BioNexus Gene Lab Corp
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M |
| Operating income | -$3.0M | -$1.6M | -$2.6M | -$291,177 | $1.1M |
| Operating expenses | $4.5M | $4.9M | $4.4M | — | — |
| Cost of revenue | $6.3M | $8.2M | $8.4M | $9.7M | $11.1M |
| Cash from operations | -$1.8M | -$2.1M | -$1.8M | $551,822 | $9,161 |
| Capital expenditure | $36,971 | $226,989 | $149,398 | $0 | $3,162 |
| Free cash flow | -$1.9M | -$2.3M | -$2.0M | $551,822 | $5,999 |
| Impairments | $0 | $40,173 | — | — | — |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M |
| Total liabilities | $637,856 | $2.1M | $1.7M | $2.1M | $2.4M |
Shares outstanding 2.4M · Free float 48.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.